Humanin: A Literature Course in Six Modules

This course organises what the published literature says about humanin, a peptide that appears in research papers under several names and analogue forms. It is structured as six modules, each ending with the limits of the evidence, followed by a closing note on what the studies did not test. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or laboratory findings. Nothing here describes a protocol, and no dosing figures are reproduced, because the purpose is to summarise what researchers studied and what they reported.

Module 1: What humanin is and how it has been studied

Definition and class

Humanin is described in the literature as a short mitochondrial-derived peptide (MDP) — a peptide encoded by an open reading frame within the mitochondrial 16S ribosomal RNA gene region (MT-RNR2) rather than by nuclear DNA. It belongs to a small family of mitochondria-encoded peptides investigated as signalling molecules rather than as structural proteins. Because humanin is an endogenous gene product, some human work measures its expression or circulating concentration rather than administering it; a 2023 report examined humanin gene expression in subjects with Parkinson's disease (PMID 36626066), and a 2026 report examined circulating humanin in chronic hemodialysis patients (PMID 41849628).

Origin within tissues and cells

Humanin has also been described as a peptide released by particular cell states. A 2025 study reported that humanin produced by human efferocytic macrophages — macrophages that had engulfed dying cells — promoted the resolution of inflammation (PMID 40877234). That framing matters for the rest of the course: much of the literature treats humanin as a locally generated stress-response signal, not as a circulating hormone with a single target organ.

Forms and analogues used in research

Papers rarely use a single molecule. Two engineered analogues dominate the animal and cell literature, and readers comparing studies need to note which form was used.

How the research has been conducted

Across the verified literature, three study designs recur: isolated-cell experiments, rodent disease models, and cross-sectional human measurement studies. Cell work includes macrophage-derived foam cells, in which Gly[14]-humanin was reported to inhibit oxidised LDL uptake and stimulate cholesterol efflux (PMID 27815075). Rodent work includes an oligoasthenozoospermia mouse model in which [Gly14]-humanin was reported to attenuate oxidative stress and ferroptosis (PMID 39435863). Human work in this set is observational.

Limits of the evidence in Module 1. The molecule studied is often an analogue, not humanin itself, so findings are not automatically interchangeable. Human data in this set describe expression or circulating levels in defined patient groups, not administration of the peptide to people. No paper in this collection reports a randomised human trial of humanin or its analogues.

Module 2: Mechanism as described in the literature

Cell-death and iron-dependent death pathways

Ferroptosis — iron-dependent, lipid-peroxidation-driven cell death — appears repeatedly as the described mechanism. Researchers reported that humanin reduced nucleus pulposus cell ferroptosis in vitro and in vivo, which the authors linked to alleviation of intervertebral disc degeneration (PMID 39902261). The same pathway was invoked in a mouse reproductive model, where [Gly14]-humanin was reported to attenuate oxidative stress and ferroptosis in oligoasthenozoospermia (PMID 39435863).

Inflammation and macrophage biology

A 2025 study described humanin as a mediator generated during efferocytosis that promoted the resolution of inflammation in human macrophages (PMID 40877234). A separate, earlier line of work described lipid handling rather than inflammatory resolution: Gly[14]-humanin was reported to inhibit ox-LDL uptake and stimulate cholesterol efflux in macrophage-derived foam cells (PMID 27815075). Both concern macrophages, but the endpoints differ.

Neuronal signalling

In neuronal preparations, the humanin derivative HNG was reported to enhance neurotransmitter release (PMID 35843407), a presynaptic mechanism distinct from the cell-survival framing used elsewhere. A separate model study examined humanin's impact on pain markers and neuronal viability in diabetic neuropathy (PMID 38599217), combining nociceptive markers with a viability endpoint.

Endocrine and metabolic framing

Two ovarian studies described mechanisms alongside their outcome measures: one reported ameliorative effects of Gly[14]-humanin on cyclophosphamide-induced premature ovarian insufficiency and investigated underlying mechanisms (PMID 40639309), and another reported that S14G-humanin ameliorated ovarian dysfunction in a comparable mouse model (PMID 40811024). In pregnancy-related metabolism, researchers reported protective effects of S14G-humanin on gestational diabetes mellitus symptoms in a model system (PMID 35536048).

Limits of the evidence in Module 2. Mechanistic descriptions are model-specific and often correlative: showing that a marker of ferroptosis or inflammation changed does not establish that the pathway caused the observed tissue outcome. Different papers propose different primary mechanisms, and no unifying receptor-level account is established across the studies listed here. Mechanism in a cell line does not predict mechanism in intact human tissue.

Module 3: Reported outcomes, study by study

The table below lists each verified report by model and endpoint area, with the outcome as the authors framed it. It is a map of the literature, not a summary of expected effects in people.

Reading the pattern

Two observations follow from the table. First, the outcomes cluster around tissue-protection endpoints in induced-injury models: chemotherapy-induced ovarian damage (PMID 40639309), glucocorticoid-associated bone changes (PMID 41550496) and disc degeneration (PMID 39902261). Second, the human entries are prognostic or descriptive: circulating humanin was studied as a risk-model variable in hemodialysis patients (PMID 41849628), and gene expression was studied in Parkinson's disease (PMID 36626066), neither of which tests the peptide as an intervention.

Limits of the evidence in Module 3. These are heterogeneous, mostly single-laboratory studies with different species, analogues, injury models and endpoints; none is a replication of another. Improvement in a chemically induced rodent model does not establish an effect in spontaneous human disease, and a biomarker that improves a statistical risk model does not show that raising or lowering it changes outcomes. No benefit in humans is established by anything in this set.

Module 4: Humanin Side Effects: What Studies Report

The honest summary is that the verified literature reviewed here contains no dedicated safety, toxicology or adverse-event study of humanin or its analogues, and adverse events are not the reported endpoint of any of these papers.

• The premature ovarian insufficiency reports were framed around ameliorative and mechanistic endpoints rather than tolerability outcomes (PMID 40639309), as was the companion S14G-humanin ovarian study (PMID 40811024).
• The Duchenne muscular dystrophy bone study reported skeletal endpoints in a glucocorticoid-treated mouse model rather than adverse-event rates (PMID 41550496), and the diabetic neuropathy study reported pain markers and neuronal viability (PMID 38599217).
• The cell-based reports — foam cell lipid handling (PMID 27815075) and macrophage inflammation resolution (PMID 40877234) — used isolated cells, a design that cannot generate clinical adverse-event data at all.

Mechanistic direction is worth noting as a research question rather than a finding. Because researchers reported that humanin analogues altered inflammation resolution (PMID 40877234) and enhanced neurotransmitter release (PMID 35843407), pathways relevant to immune and neural function were engaged in those models; whether such engagement produces unwanted effects in humans was not addressed by those studies.

Limits of the evidence in Module 4. Absence of reported adverse events in efficacy-focused animal and cell studies is not evidence of safety. No long-term exposure data, no reproductive or carcinogenicity assessment, and no human tolerability data appear in this collection.

Module 5: Pharmacokinetics, where data exist

No paper in the verified set was designed as a pharmacokinetic study, so parameters such as half-life, bioavailability, volume of distribution or clearance for humanin or its analogues are not established by these sources. What the literature does contain is measurement of endogenous humanin and its gene expression.

• Circulating humanin was quantified in chronic hemodialysis patients and evaluated as an addition to cardiovascular risk models (PMID 41849628), which demonstrates that the peptide is measurable in human blood in a clinical population.
• Humanin gene expression was assessed in subjects with Parkinson's disease (PMID 36626066), an expression-level rather than kinetic measure.
• Analogue design itself is indirectly informative: studies used engineered forms such as S14G-humanin (PMID 40811024) and [Gly14]-humanin (PMID 39435863) rather than native peptide, a common strategy in peptide research when stability or potency of the parent molecule is a limitation.

Limits of the evidence in Module 5. Detectability in plasma says nothing about what happens to administered peptide. Cross-species extrapolation of peptide kinetics is unreliable, and because the analogues differ from native humanin, kinetic behaviour cannot be assumed to be shared. Any statement about how long humanin persists in the body would be unsupported by the studies cited here.

Module 6: Regulatory status, stated factually

Regulatory facts are separate from research findings, and the two are frequently conflated in online material about mitochondrial-derived peptides.

Approved products

There is no humanin, [Gly14]-humanin or S14G-humanin product approved as a drug by the US Food and Drug Administration or the European Medicines Agency. The verified literature contains no registration trial; the human papers here are observational (PMID 41849628, PMID 36626066), and the interventional work was performed in animals and cells (PMID 41550496).

Research-use-only material

Synthetic humanin and its analogues circulate as laboratory chemicals labelled research use only (RUO). RUO labelling signifies material intended for in vitro or preclinical laboratory investigation and not evaluated or authorised for diagnosis, treatment or administration to humans. RUO status is a legal and labelling category, not a statement of quality, purity or safety.

Compounding

In the United States, a bulk drug substance may generally be used in pharmacy compounding under section 503A of the Federal Food, Drug, and Cosmetic Act only if it is the subject of a USP or NF monograph, is a component of an FDA-approved drug, or appears on the FDA's 503A bulk drug substances list; comparable criteria apply to outsourcing facilities under section 503B. Humanin does not appear as an approved-drug component in the literature reviewed here, and peptides lacking monograph or list status fall outside those compounding pathways. Some peptides have also been discussed by FDA advisory committees in the context of immunogenicity and characterisation concerns for compounded peptide substances.

This section describes publicly stated regulatory frameworks for educational purposes and is not legal advice; rules change and vary by jurisdiction.

Limits of the evidence in Module 6. Regulatory classification is time- and country-specific, and the absence of approval reflects the absence of completed clinical development programmes rather than a verdict on the underlying biology.

What the studies did not test

Reading the collection as a whole, the gaps are as instructive as the findings.

1. Human administration. No study in this set gave humanin or an analogue to people; the ovarian, testicular, bone, disc and neuropathy findings came from animal or cell models (PMID 40639309, PMID 39902261).
2. Healthy-subject outcomes. Every interventional model used induced injury or disease, such as cyclophosphamide-induced ovarian insufficiency (PMID 40811024) or glucocorticoid-treated dystrophic mice (PMID 41550496); effects in healthy organisms were not evaluated.
3. Comparative analogue testing. No study here compared native humanin with HNG and S14G-humanin head to head, even though both analogues were used separately (PMID 35843407, PMID 35536048).
4. Long-term exposure, immunogenicity and drug interactions. None of the cited reports addressed these questions, including the macrophage and foam-cell studies (PMID 40877234, PMID 27815075).
5. Clinical endpoints. Where human data exist they are prognostic associations rather than treated outcomes (PMID 41849628), and marker-level findings such as pain-marker changes are not the same as symptom relief (PMID 38599217).

Humanin therefore sits at an early stage of investigation: an endogenous mitochondrial-derived peptide with a consistent research theme of stress-response and cell-protection signalling, studied through analogues in laboratory models, without human interventional evidence, pharmacokinetic characterisation or regulatory approval in the literature summarised here.

References

• HUMANIN produced by human efferocytic macrophages promotes the resolution of inflammation (Cell Death & Disease, 2025)
• Humanin derivative, HNG, enhances neurotransmitter release (Biochimica et Biophysica Acta. General Subjects, 2022)
• Humanin gene expression in subjects with Parkinson's disease (Molecular Biology Reports, 2023)
• Ameliorative effects of Gly[14]-humanin on cyclophosphamide-induced premature ovarian insufficiency and underlying mechanisms (Reproductive BioMedicine Online, 2025)
• S14G-Humanin ameliorates ovarian dysfunction in a cyclophosphamide-induced premature ovarian insufficiency mouse model (Molecular Human Reproduction, 2025)
• Circulating Humanin Improves the Prognostic Accuracy of Cardiovascular Risk Models in Chronic Hemodialysis Patients (Cardiorenal Medicine, 2026)
• Humanin improves bone health in a glucocorticoid-treated mouse model of Duchenne muscular dystrophy (Biochemistry and Biophysics Reports, 2026)
• The protective effects of S14G-humanin on gestational diabetes mellitus symptoms (Gynecological Endocrinology, 2022)
• Humanin reduces nucleus pulposus cells ferroptosis to alleviate intervertebral disc degeneration: An in vitro and in vivo study (Journal of Orthopaedic Translation, 2025)
• Gly[14]-humanin inhibits ox-LDL uptake and stimulates cholesterol efflux in macrophage-derived foam cells (Biochemical and Biophysical Research Communications, 2017)
• Oligoasthenozoospermia is alleviated in a mouse model by [Gly14]-humanin-mediated attenuation of oxidative stress and ferroptosis (Andrology, 2025)
• Humanin's impact on pain markers and neuronal viability in diabetic neuropathy model (Archives of Physiology and Biochemistry, 2024)